Company · founded 2012
Atara Biotherapeutics (United States)
South San Francisco, United States · atarabio.com
- Citations, last 5 years
- 1 265
- Works, last 5 years
- 57
- h-index
- 39
- Scientists listed
- 5
- Grants since 2016
- 19
Grants received
2025–2026 · grant · Standard Grant
SBIR Phase I: Determination of the Mechanisms Driving Diseases at the Molecular Network Level to Develop Disruptive Drug Candidates
Julien Mamet · Atara Biotherapeutics (United States) · funded by National Science Foundation
2025–2026 · research · R44
Novel Therapeutic for SLE
Andrew Leber · Atara Biotherapeutics (United States) · funded by National Institutes of Health
2025–2026 · research · R43
Next-Gen Oral Therapeutics for Concomitant Clostridioides difficile Infection and IBD
Raquel Hontecillas · Atara Biotherapeutics (United States) · funded by National Institutes of Health
2024–2025 · research · R43
Comparative Efficacy of Therapeutics for Clostridioides difficile Infection
Raquel Hontecillas · Atara Biotherapeutics (United States) · funded by National Institutes of Health
2024–2026 · research · R43
Development of Novel Immunoregulatory Therapeutics for Asthma
Josep Bassaganya-Riera · Atara Biotherapeutics (United States) · funded by National Institutes of Health
2023–2025 · research · R43
A First-in-class Topical Immunoregulatory Therapeutic for Psoriasis
Nuria Tubau Juni · Atara Biotherapeutics (United States) · funded by National Institutes of Health
2023–2025 · research · R43
Novel first-in-class Therapeutics for Rheumatoid Arthritis
Josep Bassaganya-Riera · Atara Biotherapeutics (United States) · funded by National Institutes of Health
2023–2027 · research · R44
A First-in-class Topical Immunoregulatory Therapeutic for Psoriasis
Nuria Tubau-Juni · Atara Biotherapeutics (United States) · funded by National Institutes of Health
2022–2024 · research · R43
A Next-Generation Therapeutic for Treatment of TNFα-mediated Inflammatory Diseases
Alan F Wahl · Atara Biotherapeutics (United States) · funded by National Institutes of Health
2021–2024 · research · R44
Novel Immunoregulatory Therapeutics for Systemic Lupus Erythematosus
Andrew Leber · Atara Biotherapeutics (United States) · funded by National Institutes of Health
2020–2021 · research · R43
Developing Novel NLRX1-Based Immuno-Oncology Therapeutics
Andrew Leber · Atara Biotherapeutics (United States) · funded by National Institutes of Health
2020–2022 · research · R43
The First Pomegranate Seed Oil-Containing Medical Food for Gut and Immune Health
Raquel Hontecillas · Atara Biotherapeutics (United States) · funded by National Institutes of Health
2020–2022 · research · R41
Salmonella typhimurium-based Bacteriotherapy for Orphan Benign Tumors: Neurofibromatosis Type II (NF2)
Gary Jay Brenner · Atara Biotherapeutics (United States) · funded by National Institutes of Health
2019–2023 · research · R44
Validation of Immunometabolic NLRX1 Therapeutics for IBD
Andrew Leber · Atara Biotherapeutics (United States) · funded by National Institutes of Health
2019–2022 · research · R44
Effects of Abscisic Acid on Insulin Sensitivity
Raquel Hontecillas · Atara Biotherapeutics (United States) · funded by National Institutes of Health
2019–2020 · research · R43
Towards The Therapeutic Implementation of New CRISPR-Cas Systems
Niles Patrick Donegan · Atara Biotherapeutics (United States) · funded by National Institutes of Health
2019–2024 · research · R44
Effects of Abscisic Acid on Insulin Sensitivity
Raquel Hontecillas · Atara Biotherapeutics (United States) · funded by National Institutes of Health
2016–2017 · research · R43
The First Abscisic Acid-Containing Medical Food for Glycemic Control
Josep Bassaganya-Riera · Atara Biotherapeutics (United States) · funded by National Institutes of Health
2016–2018 · research · R44
Improved Dosing and Refinement of a Cardiac Targeted Gene Therapy in a Swine Infarct Model
Sam Teichman · Atara Biotherapeutics (United States) · funded by National Institutes of Health